AAIC 2026: Amyloid and Tau Imaging Advances

Amyloid and Tau Imaging Advances at AAIC 2026

Executive Summary

The Alzheimer's Association International Conference (AAIC) 2026 showcased transformative advances in molecular neuroimaging for Alzheimer's disease, featuring:

• Second-generation amyloid PET tracers with improved quantification and simplified clinical workflows
• Next-generation tau PET agents with reduced off-target binding and broader disease applicability
• FDA approval progress for blood-based p-tau biomarkers (p-tau217, p-tau181)
• Integrated biomarker platforms combining PET imaging with fluid biomarkers for comprehensive assessment
• Clinical implementation frameworks enabling point-of-care testing in primary care settings

These advances represent a paradigm shift toward biologically-defined AD diagnosis and treatment selection, moving beyond clinical criteria alone.

Amyloid PET Imaging Advances

Evolution of Amyloid Radiotracers

Amyloid PET has evolved significantly since the introduction of Pittsburgh Compound-B (PiB) in 2004[@klunk2004]:

| Generation | Tracers | Key Advances |
|------------|---------|--------------|
| First-generation | 11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben | Clinical approval, validation |
| Second-generation | Improved 18F-tracers with better kinetics | Faster clearance, reduced off-target |

Centiloid Scale Standardization

The Centiloid (CL) scale has become the standard metric for amyloid quantification[@navitsky2018]:

...

Amyloid and Tau Imaging Advances at AAIC 2026

Executive Summary

The Alzheimer's Association International Conference (AAIC) 2026 showcased transformative advances in molecular neuroimaging for Alzheimer's disease, featuring:

• Second-generation amyloid PET tracers with improved quantification and simplified clinical workflows
• Next-generation tau PET agents with reduced off-target binding and broader disease applicability
• FDA approval progress for blood-based p-tau biomarkers (p-tau217, p-tau181)
• Integrated biomarker platforms combining PET imaging with fluid biomarkers for comprehensive assessment
• Clinical implementation frameworks enabling point-of-care testing in primary care settings

These advances represent a paradigm shift toward biologically-defined AD diagnosis and treatment selection, moving beyond clinical criteria alone.

Amyloid PET Imaging Advances

Evolution of Amyloid Radiotracers

Amyloid PET has evolved significantly since the introduction of Pittsburgh Compound-B (PiB) in 2004[@klunk2004]:

| Generation | Tracers | Key Advances |
|------------|---------|--------------|
| First-generation | 11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben | Clinical approval, validation |
| Second-generation | Improved 18F-tracers with better kinetics | Faster clearance, reduced off-target |

Centiloid Scale Standardization

The Centiloid (CL) scale has become the standard metric for amyloid quantification[@navitsky2018]:

• 0 CL: Mean signal in young healthy individuals (negative for amyloid)
• 100 CL: Mean signal in typical AD patients
• Threshold: >20-25 CL typically considered amyloid-positive
• Clinical cutoff: Often set at 30 CL for treatment decisions

Second-Generation Amyloid Tracers

AAIC 2026 featured advances in amyloid PET technology:

| Tracer | Characteristics | Status |
|--------|-----------------|--------|
| 18F-Florbetapir (Amyvid) | FDA-approved, widely used | Clinical standard |
| 18F-Flutemetamol (Vizamyl) | FDA-approved, thioflavin analog | Clinical standard |
| 18F-Florbetaben (Neuraceq) | FDA-approved for beta-amyloid | Clinical standard |
| 18F-AK01 | Improved signal-to-noise | Phase 3 |

Amyloid PET in Anti-Amyloid Therapy

Amyloid PET is essential for patient selection and treatment monitoring:

| Therapy | Amyloid PET Requirement | Monitoring |
|---------|------------------------|------------|
| Lecanemab (Leqembi) | Amyloid-positive MCI or AD | SUVr reduction at 18 months |
| Donanemab | Amyloid-positive early AD | Plaque clearance (CL < 10) |
| Aducanumab | Amyloid-positive AD | Dose selection, target engagement |

Tau PET Imaging Advances

First vs. Second-Generation Tau Tracers

AAIC 2026 highlighted the transition from first to second-generation tau PET agents[@fleisher2024]:

| Property | First-Generation | Second-Generation |
|----------|-------------------|-------------------|
| Off-target binding | High (basal ganglia, choroid plexus) | Minimal |
| Quantification | Complex SUVr methods | Simplified visual read |
| Disease applicability | AD only | AD + primary tauopathies |
| Early detection | Limited | Preclinical detection |

Key Tau PET Tracers

FDA-Approved

Flortaucipir (Tauvid, 18F-AV-1451)

• First and only FDA-approved tau PET tracer
• Indicated for amyloid-positive adults with MCI or dementia due to AD
• Acquisition: 80-100 minutes post-injection
• Limitations: Off-target binding in basal ganglia, limited 3R/4R detection

Second-Generation in Development

| Tracer | Developer | Key Features | Status |
|--------|-----------|--------------|--------|
| MK-6240 | Merck | Higher PHF-tau specificity | Phase 3 |
| PI-2620 | Life Molecular Imaging | 3R/4R detection (PSP, CBD) | Phase 2/3 |
| APN-1607 | Aprinoia | Broad tauopathy applicability | Phase 2 |
| RO-948 | Roche | Early detection | Phase 2 |
| JNJ-311 | J&J | Novel binding profile | Phase 1 |

Tau PET Disease Staging

Tau PET enables in vivo Braak staging:

| Braak Stage | Regions Affected | Clinical Correlation |
|-------------|------------------|---------------------|
| I-II | Transentorhinal cortex | Preclinical AD |
| III-IV | Limbic (hippocampus, entorhinal) | MCI to mild AD |
| V-VI | Isocortical (frontal, parietal) | Moderate to severe AD |

Tau PET in Clinical Trials

Tau PET serves as both enrichment biomarker and outcome measure:

| Trial Phase | Tau PET Application |
|-------------|---------------------|
| Phase 1 | Target engagement, dose selection |
| Phase 2 | Patient stratification, mechanism validation |
| Phase 3 | Disease modification endpoints |

AAIC 2026 Anti-Tau Updates:

• Semorinemab (Roche): Phase 2 showed tau PET reduction in temporal cortex
• Zagotenemab (Eli Lilly): Mid-domain targeting showing promising results
• JNJ-63733657 (J&J): Phospho-tau specific antibody in Phase 1

Fluid Biomarker Integration

Blood-Based Biomarker Advances

AAIC 2026 featured major advances in blood-based biomarkers[@palmqvist2024]:

| Biomarker | Current Status | Clinical Utility |
|-----------|----------------|------------------|
| p-Tau217 | FDA review pending | Highest specificity, >95% sensitivity |
| p-Tau181 | FDA-cleared (multiple platforms) | Widely available, screening |
| p-Tau231 | Research stage | Earliest detectable marker |
| GFAP | FDA-cleared | Astrocyte activation, amyloid reactivity |

Diagnostic Performance

Blood biomarkers demonstrate exceptional performance[@blennow2024]:

| Panel Composition | AUC for AD vs. Controls |
|-------------------|------------------------|
| p-tau217 + GFAP | 0.95-0.97 |
| p-tau181 + NfL | 0.92-0.94 |
| p-tau217 + GFAP + NfL | 0.96-0.98 |
| p-tau217 + GFAP + Aβ42/40 | 0.97-0.99 |

PET-Fluid Biomarker Correlation

| PET Measure | Fluid Biomarker Correlation |
|-------------|----------------------------|
| Amyloid PET (Centiloid) | p-tau217 (r=0.82-0.89), Aβ42/40 (r=0.75-0.85) |
| Tau PET (Braak ROI) | p-tau217 (r=0.78-0.86), p-tau181 (r=0.70-0.80) |
| Neurodegeneration (FDG-PET) | NfL (r=0.65-0.75), p-tau181 (r=0.60-0.70) |

AT(N) Framework Evolution

Expansion to Blood-Based Biomarkers

The AT(N) framework has evolved to incorporate blood-based markers[@jack2022]:

• AT(Blood): Blood-based amyloid, tau, neurodegeneration markers
• Combined panels: All AT(N) markers from single blood draw
• Multimodal integration: PET + MRI + fluid biomarker combinations

Clinical Decision Framework

| Scenario | Recommended Biomarkers |
|----------|----------------------|
| Routine screening | p-tau181 (primary care) |
| Confirmatory testing | p-tau217 (specialty) |
| Comprehensive assessment | Full AT(N) panel + PET |
| Treatment selection | Amyloid PET required |
| Treatment monitoring | p-tau217, NfL, amyloid PET |

Clinical Implementation

Regulatory Status

FDA pathway updates:

• Multiple p-tau assays under FDA review (2026-2027 decisions expected)
• FDA guidance on validation requirements published
• Medicare coverage pending FDA clearance

Implementation Framework

Two-tiered clinical approach:

Initial screening: p-tau181 in primary care

Confirmatory testing: p-tau217 for complex cases

Comprehensive assessment: Full biomarker panel in specialized settings

Health Equity Considerations

• Ancestry-specific cutoffs validated in diverse populations
• Point-of-care testing for under-resourced settings
• Dried blood spot approaches for broader access

Future Directions

Emerging Technologies

| Technology | Potential Impact |
|-------------|------------------|
| Point-of-care lateral flow assays | Primary care screening |
| Dried blood spot testing | Broader accessibility |
| Tau oligomer detection | Earlier, more specific detection |
| Exosomal tau | Brain-region specific signals |

Research Priorities

Standardization: Cross-platform harmonization

Accessibility: Point-of-care testing

Integration: Electronic health record incorporation

Education: Clinician training on appropriate use

Related NeuroWiki Content

Biomarker Pages

• [Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)
• [Tau PET Imaging](/biomarkers/tau-pet-imaging)
• [p-Tau217](/biomarkers/p-tau-217)
• [p-Tau181](/biomarkers/p-tau-181)
• [GFAP](/biomarkers/gfap-alzheimers)
• [Blood-Based Biomarkers](/mechanisms/blood-based-biomarkers)
• [AT(N) Biomarker Classification](/mechanisms/alzheimers-disease-biomarker-temporal-sequence-hypothesis)

Therapeutic Pages

• [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-therapeutics)
• [Lecanemab](/therapeutics/lecanemab)
• [Anti-Tau Immunotherapy](/therapeutics/anti-tau-immunotherapies)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)

Event Content

• [AAIC 2026 Conference](/events/aaic-2026)
• [AAIC 2026: Tau Imaging and Biomarker Validation](/events/aaic-2026-tau-imaging-biomarker-validation)
• [AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)

References

[Klunk WE, et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (PiB) (2004)](https://doi.org/10.1093/brain/awh349)

[Navitsky M, et al., Standardization of amyloid quantitation with florbetapir PET to the Centiloid scale (2018)](https://doi.org/10.1016/j.neuroimage.2018.06.079)

[Mintun MA, et al., FLORTauCIPIR (F 18 AV-1451) PET imaging in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32031504/)

[Fleisher AS, et al., Tau PET imaging: optimizing detection and quantification (2024)](https://pubmed.ncbi.nlm.nih.gov/38942015/)

[Palmqvist S, et al., Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38597015/)

[Jack CR Jr, et al., AT(N): A Research Framework for Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35645193/)

[Blennow K, et al., Blood biomarkers for Alzheimer's disease: current status and future directions (2024)](https://pubmed.ncbi.nlm.nih.gov/38456347/)

[Cummings J, et al., Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)